Massachusetts Financial Services Co. MA reduced its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 3.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 78,042 shares of the company’s stock after selling 2,990 shares during the period. Massachusetts Financial Services Co. MA owned 0.11% of Kiniksa Pharmaceuticals worth $1,356,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Kiniksa Pharmaceuticals by 7.9% in the third quarter. Barclays PLC now owns 175,525 shares of the company’s stock valued at $3,048,000 after acquiring an additional 12,867 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $176,000. Capula Management Ltd bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $892,000. Principal Financial Group Inc. acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at approximately $777,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in Kiniksa Pharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 55,047 shares of the company’s stock valued at $956,000 after buying an additional 26,002 shares during the period. Institutional investors own 47.31% of the company’s stock.
Kiniksa Pharmaceuticals Stock Performance
Shares of NASDAQ:KNSA opened at $20.55 on Tuesday. The company has a 50 day moving average price of $18.39 and a two-hundred day moving average price of $17.27. The company has a market capitalization of $1.45 billion, a PE ratio of -186.80 and a beta of 0.24. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $10.29 and a 52 week high of $20.94.
Insider Buying and Selling
Analysts Set New Price Targets
KNSA has been the subject of several recent research reports. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $23.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, January 2nd. TheStreet downgraded Kiniksa Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, November 3rd.
Kiniksa Pharmaceuticals Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
- Five stocks we like better than Kiniksa Pharmaceuticals
- How to Invest in the Best Canadian Stocks
- 3 attractive stocks that insiders are buying
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Consumer Discretionary Stocks Explained
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.